native MUC1 peptide

Native MUC1 peptide refers to unmodified, unglycosylated peptide sequences derived from the variable number of tandem repeats (VNTR) or other regions of the Mucin 1 (MUC1) glycoprotein. MUC1 is a cell-surface glycoprotein that is overexpressed and aberrantly glycosylated in a wide variety of epithelial cancers, including breast, pancreatic, ovarian, and colorectal cancers. Native MUC1 peptides have been investigated as cancer vaccines designed to stimulate the host immune system, particularly by generating MUC1-specific cytotoxic T lymphocytes (CTLs) to target and destroy MUC1-expressing tumor cells. However, clinical trials using native, unglycosylated MUC1 peptides have often shown limited clinical efficacy due to immunological tolerance to the self-antigen and low binding affinity to MHC molecules, prompting the development of modified, heteroclitic, or glycosylated MUC1 peptide analogs.

Other names

native MUC1 peptide vaccineunglycosylated MUC1 peptideunmodified MUC1 peptide